Goldenwell Biotech (GWLL) Total Current Liabilities (2021 - 2025)

Goldenwell Biotech has reported Total Current Liabilities for 4 years, with the latest figure at $39360.0 in Q3 2025.

• For the quarter ending Q3 2025, Total Current Liabilities changed N/A year-over-year to $39360.0; the trailing twelve-month figure through Sep 2025 stood at $39360.0 (changed N/A YoY), and the FY2024 full-year result was $1860.0, changed N/A from the prior year.
• Total Current Liabilities for Q3 2025 stood at $39360.0, down from $64360.0 in the prior quarter.
• The five-year high for Total Current Liabilities was $159266.0 in Q4 2021, with the low at $1860.0 in Q4 2024.
• Historically, Total Current Liabilities has averaged $61648.8 across 4 years, with a median of $39856.0 in 2022.
• The largest YoY upside for Total Current Liabilities was 76.88% in 2022 against a maximum downside of 76.88% in 2022.
• Goldenwell Biotech's Total Current Liabilities stood at $159266.0 in 2021, then slumped by 81.71% to $29126.0 in 2022, then tumbled by 93.61% to $1860.0 in 2024, then soared by 2016.13% to $39360.0 in 2025.
• The last three Total Current Liabilities figures came in at $39360.0 (Q3 2025), $64360.0 (Q2 2025), and $1860.0 (Q4 2024), per Business Quant data.